FREEHOLD, NJ--(Marketwired - Jul 15, 2016) - MEDIFIRST SOLUTIONS, INC. (OTC PINK: MFST) (the "Company" or "Medifirst") would like to update shareholders regarding a major company development. On July 8, 2016, Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA") to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.

Commented President Bruce J. Schoengood, "This is a milestone event for Medifirst and we are thrilled to have received the FDA clearance. The company will now move into the next phase of operations which includes developing and implementing sales, marketing and continued FDA compliance. We can now focus our attention toward introducing The Time Machine Laser to the medical and healthcare marketplace and begin to ramp up internal operations. This a very exciting time for the company and we'd like to thank our shareholders for their continued confidence and support. The Company intends to update shareholders on its operational strategies in the upcoming weeks."

About Medifirst Solutions, Inc.

Medifirst Solutions, Inc. is a Nevada corporation that is headquartered in New Jersey. The company seeks innovative medical and healthcare products and technologies which are targeted to both medical and healthcare professionals, as well as everyday consumers. Medifirst is developing and establishing both consumer and professional medical cliental that can serve as a pipeline that will allow for distribution of future products and services. For more details visit for more information.

About the Lasers

Medical Lasers Manufacturer, Inc., a Nevada company, ("MLM"), a Medifirst subsidiary, will specialize in producing high quality diode-pumped solid-state lasers. The laser division, including products and treatment programs, will be operated out of MLM. The company's focus is to help patients with specific cosmetic skin conditions, as well as relief of muscle and joint pain and muscle spasm and inflammation.

Forward-Looking Statements: The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements.

Contact Information:

Medifirst Solutions, Inc.
Investor Relations
(732) 786-8044